Advantage Alpha Capital Partners LP Castle Biosciences Inc Transaction History
Advantage Alpha Capital Partners LP
- $337 Million
- Q2 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 16,021 shares of CSTL stock, worth $363,997. This represents 0.1% of its overall portfolio holdings.
Number of Shares
16,021
Previous 19,805
19.11%
Holding current value
$363,997
Previous $396,000
17.42%
% of portfolio
0.1%
Previous 0.11%
Shares
3 transactions
Others Institutions Holding CSTL
# of Institutions
165Shares Held
27.2MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$69.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$49.3 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$40.9 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.49MShares$33.8 Million2.2% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$31.3 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $597M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...